Shionogi's RADICAVA ORS Marks Four Years in ALS Treatment — Shionogi Inc.

Event summary

RADICAVA ORS, the oral formulation of edaravone for ALS treatment, celebrated its four-year anniversary since FDA approval in May 2022.
Approximately 1,640 U.S. physicians have prescribed RADICAVA ORS to over 4,500 patients, with about 810 physicians prescribing it monthly.
The oral formulation offers the same efficacy as the intravenous version but avoids the burdens of IV administration.
Shionogi highlights its commitment to ALS research through real-world evidence and biomarker studies.

The big picture

Shionogi's RADICAVA ORS represents a significant advancement in ALS treatment, offering an oral alternative to IV administration. The drug's adoption by over 1,600 physicians and its use in treating more than 4,500 patients highlight its growing role in managing this progressive neurodegenerative disease. Shionogi's continued investment in ALS research underscores the urgent need for innovative therapies in a market with limited treatment options.

What we're watching

Market Penetration: Whether Shionogi can sustain the current adoption rate of RADICAVA ORS among U.S. physicians and patients.
Regulatory Dynamics: The pace at which additional regulatory approvals for RADICAVA ORS will be granted in other countries.
Competitive Landscape: How Shionogi's focus on ALS research and real-world evidence will position it against emerging therapies in the ALS treatment space.